A comparison of different protease inhibitors on coronary heart disease risk

Connecticut Medicine

Volumn 71, Issue 1, 2007, Pages 15-17

  Coleman, Craig I ^c   White, C Michael ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DRUG EFFECT; DRUG INFORMATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; CORONARY DISEASE; HIV PROTEASE INHIBITORS; HIV SEROPOSITIVITY; HUMANS; HYPERLIPIDEMIAS; NELFINAVIR; OLIGOPEPTIDES; PYRIDINES; RISK FACTORS;

EID: 33846694796     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. CDC HIV/AIDS Surveillance Report. Available at: www.cdc.gov/hiv/stats.htm (accessed 7/12/2003).
2. Panel on Clinical Practices for Treatment of HIV Infection, convened by Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (July 14, 2003). Available from: URL: http://AIDSinfo.nih.gov (accessed 8/1/2003).
3. Hammer SM, Squires KE. Hughes MD, et al: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millmeter or less. N Engl J Med 1997; 337:725-33.
4. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg S, Buchbinder S: Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179:717-20.
5. Dube MP, Sprecher D, Henry WK, et al: Prelimanry guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clin Infect Dis 2000; 31:1216-24.
6. Piliero P, Cahn P, Pantaleo G, et al: Atazanavir: A once daily protease inhibitor with a superior lipid profile: Results of clinical trials beyond week 48. Presented at: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, February 24-28, 2002, abstract 706.
7. Sanne I, Piliero P, Squires K, et al: Results of a Phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr. 2003; 32:18-29.
8. Sanne I, Cahn P, Percival L, et al: Comparative Results (Phase 11 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naïve HIV(+) Patients (AI424-008). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, December 16-19, 2002, abstract 1-667.
9. Murphy R, Pokrovskiy V, Rozenbaum W, et al: Long-term efficacy and safety of Atazanavir with stavudine and lamuvidine in patients previously treated with nelfmavir or ATV: 108-week results of BMS study 008/044). Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 10-14, 2003, abstract 555.
10. Haas D, Zala C, Schrader S, et al: Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003; 17:1339-49.
11. Squires KE, Thiry A, Giordano M: Atazanavir (ATV) QD and Efavirenz (EFV) QD with fixed dose ZDV + 3TC: Comparison of antiviral efficacy and safety through week 24 (AI423-034). Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 27-30, 2000, abstract H-1076.
12. Rosenberg PS, Biggar RJ, Goedert JJ: Declining age at HIV infection in the United States [letter]. N Engl J Med 1994;330:789-90).
13. Wilson PWF, D'Agostino RB, Levy D, et al: Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
15. Nieto-Cisneros L, Zala C, Fessel WJ, et al: Antiviral efficacy, metabolic changes and safety of atazanavir (ATV) versus lopinavir/ritonavir (LPV/RTV) in combination with 2 NRTIs in patients who have experienced virologic failure with prior PI-containing regimen(s): 24-week results from BMS AI424-043. Antivir Ther. 2003; 8(suppl. 1):S212. Abstract 117.
16. Badaro R, DeJesus E, Lazzarin A, et al: Atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) vs lopinavir/ritonavir (LPV/RTV) in patients with multiple virologic failures: 24 week results from BMS AI424-045. Presented at: 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 13-16, 2003, abstract 118.